JP2009523828A5 - - Google Patents

Info

Publication number

JP2009523828A5

JP2009523828A5 JP2008551553A JP2008551553A JP2009523828A5 JP 2009523828 A5 JP2009523828 A5 JP 2009523828A5 JP 2008551553 A JP2008551553 A JP 2008551553A JP 2008551553 A JP2008551553 A JP 2008551553A JP 2009523828 A5 JP2009523828 A5 JP 2009523828A5

Authority

JP

Japan

Prior art keywords

hvr

antibody

ephrin

seq

host cell

Prior art date

2007-01-19

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 claims 13
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
• 238000006467 substitution reaction Methods 0.000 claims 9
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 8
• 201000010099 disease Diseases 0.000 claims 8
• 239000003814 drug Substances 0.000 claims 6
• 239000013598 vector Substances 0.000 claims 6
• 206010028980 Neoplasm Diseases 0.000 claims 4
• 230000033115 angiogenesis Effects 0.000 claims 4
• 239000004037 angiogenesis inhibitor Substances 0.000 claims 4
• 102000006396 Ephrin-B2 Human genes 0.000 claims 3
• 108010044090 Ephrin-B2 Proteins 0.000 claims 3
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 3
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
• 230000001575 pathological effect Effects 0.000 claims 3
• 102000040430 polynucleotide Human genes 0.000 claims 3
• 108091033319 polynucleotide Proteins 0.000 claims 3
• 239000002157 polynucleotide Substances 0.000 claims 3
• 239000005557 antagonist Substances 0.000 claims 2
• 239000012472 biological sample Substances 0.000 claims 2
• 201000011510 cancer Diseases 0.000 claims 2
• 102000012803 ephrin Human genes 0.000 claims 2
• 108060002566 ephrin Proteins 0.000 claims 2
• 238000004519 manufacturing process Methods 0.000 claims 2
• 238000012986 modification Methods 0.000 claims 2
• 230000004048 modification Effects 0.000 claims 2
• 230000002062 proliferating effect Effects 0.000 claims 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
• 102220582564 4-hydroxy-2-oxoglutarate aldolase, mitochondrial_N78A_mutation Human genes 0.000 claims 1
• 241000124008 Mammalia Species 0.000 claims 1
• 102220492945 Nuclear RNA export factor 1_R71A_mutation Human genes 0.000 claims 1
• 102220506801 Vitelline membrane outer layer protein 1 homolog_N73T_mutation Human genes 0.000 claims 1
• 239000002246 antineoplastic agent Substances 0.000 claims 1
• 229960000397 bevacizumab Drugs 0.000 claims 1
• 229940127089 cytotoxic agent Drugs 0.000 claims 1
• 238000012217 deletion Methods 0.000 claims 1
• 230000037430 deletion Effects 0.000 claims 1
• 239000013604 expression vector Substances 0.000 claims 1
• 229910052739 hydrogen Inorganic materials 0.000 claims 1
• 229940127121 immunoconjugate Drugs 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 238000003780 insertion Methods 0.000 claims 1
• 230000037431 insertion Effects 0.000 claims 1
• 230000004770 neurodegeneration Effects 0.000 claims 1
• 208000015122 neurodegenerative disease Diseases 0.000 claims 1
• 201000001119 neuropathy Diseases 0.000 claims 1
• 230000007823 neuropathy Effects 0.000 claims 1
• 208000033808 peripheral neuropathy Diseases 0.000 claims 1
• 238000011321 prophylaxis Methods 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 claims 1
• 238000011282 treatment Methods 0.000 claims 1